Do not use bisphosphonate therapy indefinitely for fracture prevention.
A placebo-controlled trial showed that the limited clinical benefits of continuing treatment after 5 years do not justify the risk of adverse effects.
D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D005598:Fractures, Spontaneous / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D004164:Diphosphonates; D019386:Alendronate